Two new HCV meds have been approved over the summer. This webinar is meant to provide an update on how these fit into current practice. We will also cover the ongoing controversy on the risk of HCC with DAA's and the recent Cochrane report on the benefits of HCV therapy.Insook Kim (Moderator) Insook Kim, PhD is a clinical pharmacology team leader for gastroenterology and hepatology products in the Office of Clinical Pharmacology at FDA.

Richard S. Finn, Andrew X. Zhu, Wigdan Farah, Jehad Almasri, Feras Zaiem, Larry J. Prokop, Mohammad Hassan Murad, Khaled Mohammed – 7 September 2017 – Hepatocellular carcinoma (HCC) is a complex disease most commonly arising in the background of chronic liver disease. In the past two decades, there has been a significant increase in our understanding of both the clinical and molecular heterogeneity of HCC. There has been a robust increase in clinical trial activity in patients with poor prognostic factors, such as macrovascular invasion and extrahepatic spread (EHS).

Keely Marshall, Junfei Jin, Carl Atkinson, Ali Alawieh, Fei Qiao, Biao Lei, Kenneth D. Chavin, Songqing He, Stephen Tomlinson – 7 September 2017 – Complement plays a role in both hepatic ischemia reperfusion (IR) injury (IRI) and liver regeneration, but it is not clear how complement is activated in either process. We investigated the role of self‐reactive immunoglobulin M (IgM) antibodies in activating complement after hepatic IR and liver resection.

Richard S. Finn, Andrew X. Zhu, Wigdan Farah, Jehad Almasri, Feras Zaiem, Larry J. Prokop, Mohammad Hassan Murad, Khaled Mohammed – 7 September 2017 – Hepatocellular carcinoma (HCC) is a complex disease most commonly arising in the background of chronic liver disease. In the past two decades, there has been a significant increase in our understanding of both the clinical and molecular heterogeneity of HCC. There has been a robust increase in clinical trial activity in patients with poor prognostic factors, such as macrovascular invasion and extrahepatic spread (EHS).

Harvey Alter, Timothy Block, Nathaniel Brown, Alan Brownstein, Carol Brosgart, Kyong‐Mi Chang, Pei‐Jer Chen, Francis V. Chisari, Chari Cohen, Hashem El‐Serag, Jordan Feld, Robert Gish, Jeffrey Glenn, Tim Greten, Haitao Guo, Ju‐Tao Guo, Yujin Hoshida, Jianming Hu, Kris V. Kowdley, Wenhui Li, Jake Liang, Stephan Locarnini, Anna S. Lok, William Mason, Brian McMahon, Anand Mehta, Robert Perrillo, Peter Revill, Charles M. Rice, JoAnn Rinaudo, Raymond Schinazi, Christoph Seeger, Kirty Shetty, John Tavis, Fabien Zoulim – 6 September 2017

Virginia Hernández‐Gea, Christophe Bureau – 5 September 2017

5 September 2017

Haesuk Park, Chao Chen, Wei Wang, Linda Henry, Robert L. Cook, David R. Nelson – 5 September 2017 – We assessed the risk of chronic kidney disease (CKD) in chronic hepatitis C virus (HCV)‐infected patients and the incidence reduction of CKD after receipt of HCV treatment. We also evaluated the risk of membranoproliferative glomerulonephritis (MPGN) and cryoglobulinemia in chronic HCV patients. A retrospective cohort analysis of the Truven Health MarketScan Database (2008‐2015) in the United States was conducted.

Patrick Borentain, Philippe Colson, Emilie Bolon, Philippe Gauchez, Diane Coso, René Gérolami – 5 September 2017

Hans Reinke, Gad Asher – 5 September 2017